Aadi bioscience provides precision1 trial and corporate updates

Precision1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted aadi will focus on fyarro® commercial business for its approved indication, pecoma, and conduct a comprehensive strategic review to maximize shareholder value to further preserve cash position, aadi will adjust ongoing phase 2 trials and reduce r&d headcount by 80%, thereby extending cash runway into at least 2h 2026 los angeles , aug. 20, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi) today announced it will halt the registration-intended precision1 trial of nab-sirolimus in patients with solid tumors harboring tsc1 or tsc2 inactivating alterations. an analysis by the independent data monitoring committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this phase 2 study.
AADI Ratings Summary
AADI Quant Ranking